CTOs on the Move

La Casa Assisted Living

www.lacasaassistedliving.com

 
La Casa Assisted Living is a Merritt Island, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 10K-50K
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

The Valens Company

The Valens Company (TSX:VLNS) (OTCQX:VLNCF) is a multi-licensed, vertically-integrated cannabis company focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and white-label product development. The Valens Company is the largest third-party extraction Company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. Additionally, our subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science.

Ash Stevens Inc

Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to

Industrial Biotechnology Corporation

Industrial Biotechnology Corporation is a Sarasota, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agena Bioscience

Agena Bioscience’s scalable MassARRAY System enables one day assay turnaround times on a wide variety of targeted genetic tests.

GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.